How has been the historical performance of Dhampur Bio?

Answer:The historical performance of Dhampur Bio shows a fluctuating trend in key financial metrics over the past four years.

Breakdown:
In terms of net sales, Dhampur Bio reported 1,861.54 Cr in March 2025, a slight decrease from 1,864.44 Cr in March 2024, and a significant drop from 2,407.53 Cr in March 2023. The total operating income mirrored this trend, with figures of 1,861.54 Cr in March 2025, 1,864.44 Cr in March 2024, and 2,407.53 Cr in March 2023. The total expenditure, excluding depreciation, was 1,726.74 Cr in March 2025, showing a decrease from 1,728.01 Cr in March 2024 and a notable decline from 2,202.81 Cr in March 2023. Operating profit (PBDIT) was 138.46 Cr in March 2025, down from 160.30 Cr in March 2024 and 216.14 Cr in March 2023. Profit before tax also decreased significantly to 15.71 Cr in March 2025 from 65.49 Cr in March 2024 and 134.77 Cr in March 2023. Consequently, profit after tax fell to 14.69 Cr in March 2025, compared to 46.49 Cr in March 2024 and 111.10 Cr in March 2023. The earnings per share (EPS) reflected this decline, dropping to 2.21 in March 2025 from 7.0 in March 2024 and 16.73 in March 2023. On the balance sheet, total liabilities increased to 2,397.53 Cr in March 2025 from 2,312.81 Cr in March 2024 and 2,077.46 Cr in March 2023, while total assets also rose to 2,397.53 Cr in March 2025 from 2,312.81 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -101.00 Cr in March 2024, down from 368.00 Cr in March 2023. Overall, the financial performance of Dhampur Bio indicates challenges in maintaining profitability and managing costs effectively over the observed period.